Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy

AIDS

Volumn 15, Issue 8, 2001, Pages 975-982

  Huang, Jeannie S ^a   Rietschel, Petra ^a   Hadigan, Colleen M ^a   Rosenthal, Daniel I ^a   Grinspoon, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Bone density; HIV; Lipodystrophy

Indexed keywords

PROTEINASE INHIBITOR;

ABDOMEN; ADULT; BODY FAT; BONE DENSITY; BONE TURNOVER; CALCIUM METABOLISM; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; PRIORITY JOURNAL;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; BODY COMPOSITION; BONE DENSITY; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPODYSTROPHY; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0035947320     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200105250-00005     Document Type: Conference Paper

References (28)

1. 1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12;F51-F58.
2. 2. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy; preliminary results of the LIPOCO study. AIDS 2000, 14:37-49.
3. 3. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14;F63-F67.
4. 4. Kanis J, Johnell O, Gullberg B, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int 1999, 9:45-54.
5. 5. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86:504-510.
6. 6. Centers for Disease Control and Prevention. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:RR-17.
7. 7. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA 2000, 284:472-477.
8. 8. Katznelson L, Rosenthal DI, Rosol MS, et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. Am J Roentgenol 1998, 170:423-427.
9. nd edn. New York: McGraw-Hill Book Company, Inc., 1957.
10. 10. Cann CE, Genant HK. Cross-sectional studies of vertebral mineral using quantitative computed tomography. J Comput Assist Tomogr 1982, 6:216.
11. 11. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12:1645-1651.
12. 12. Paton NIJ, Macallan DC, Griffin GE, et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997, 61:30-32.
13. th Meeting of ICAAC. Toronto, September 2000.
14. 14. Lang TF, Li J, Harris ST, et al. Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 1999, 23:130-137.
15. 15. Nolan D, Upton R, James I, et al. Longitudinal analysis of bone mineral density (BMD) in HIV-infected patients treated with HAART: changes in BMD correlate with change in subcutaneous fat; with an additional independent effect of indinavir therapy to increase BMD. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract 031].
16. 16. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145-150.
17. 17. Serrano S, Marinoso ML, Soriano JC, et al. Bone remodeling in human immunodeficiency virus-1 infected patients. A histomorphometric study. Bone 1995, 16:185-191.
18. 18. Tebas P, Yarasheski KE, Whyte M, et al. Serum and urine markers of bone mineral metabolism in HIV infected patients taking protease inhibitor containing potent antiretroviral therapy. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract 029].
19. 19. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977, 91:335-344.
20. 20. Howlett CR, Cave J, Williamson M, et al. Mineralization in in vitro cultures of rabbit marrow stromal cells. Clin Orthop 1986, 213:251-263.
21. 21. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-208.
22. 22. Richardson ML, Genant HK, Cann CE, et al. Assessment of metabolic bone diseases by quantitative computed tomography. Clin Orthop 1985, 195:224-238.
23. 23. Faul DD, Couch JL, Cann CD, et al. Composition-selective reconstruction for mineral content in the axial and appendicular skeleton. J Comput Assist Tomogr 1982, 6:202-203.
24. th IDSA Meeting. New Orleans, September 2000 [abstract 15].
25. 25. Stephens EA, Das R, Madge S, et al. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999, 13:2605-2606.
26. 26. Carr A, Miller J, Cooper DA, Osteopenia in HIV-infected men: association with lactic academia and lower weight pre-antiretroviral therapy. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract 032].
27. 27. Grinspoon SK, Baum HBA, Kim V, Coggins C, Klibanski A. Decreased bone formation and increased mineral dissolution during acute fasting in young women. J Endocrinol Metab 1995, 80:3628-3633.
28. 28. Wang MWH, Teitelbaum SL, Tebas P, Powderly WG, Ross FP. Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function. Retrovirus 2001. Chicago. February 2001 [abstract 541].